Join our webinar for insights on the journey from preclinical to clinical studies in pulmonary arterial hypertension (PAH), and much more.
Overview
This webinar represents a collective effort to propel the knowledge exchange within our community. It offers a unique opportunity to deepen your understanding, engage in critical discussions, and foster collaborations in this rapidly evolving field.
Objective
Distinguished experts from University Hospital of Antwerp and SGS, unravel the latest advancements from preclinical to clinical studies in pulmonary arterial hypertension (PAH). They will give profound insights into current treatments, late-phase Investigational Medicinal Products (IMPs) and early-stage innovations tailored for this indication.
Agenda
- Current standard of care for PAH treatment
- Innovations in late-phase IMPs and vaccinations
- Preclinical and early phase developments in this field
- Q&A session: engage with experts, clarify your concerns
Target Audience: The webinar is aimed at all pharmaceutical and biotech professionals, as well as esteemed pulmonologists, general practitioners, cardiologists and clinicians.
Language: English
Can't make a live session? Register now and receive a complimentary recording after the live event.
For English and French speakers
For German and Italian speakers
Technoparkstrasse 1,
8005, Zurich, Switzerland